Amphastar Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-12$29.40 RISE2026-03-13$18.18 PEAK2026-05-07$24.03 115d | -38.2% 60d | Missed | Missed | — | — | +32.2% 55d | Missed |
DROP2026-01-12$29.40 RISE2026-03-12$18.18 PEAK2026-05-07$24.03 115d | -38.2% 59d | Missed | Missed | — | — | +32.2% 56d | Missed |
DROP2025-09-02$30.81 RISE2025-12-12$25.27 PEAK2026-01-12$29.40 132d | -18.0% 101d | Missed | Missed | — | — | +16.3% 31d | Missed |
DROP2025-09-02$30.81 RISE2025-10-15$23.14 PEAK2026-01-12$29.40 132d | -24.9% 43d | Missed | Missed | — | — | +27.1% 89d | Missed |
DROP2025-03-31$28.99 RISE2025-07-18$20.62 PEAK2025-09-02$30.81 155d | -28.9% 109d | Missed | Missed | — | — | +49.4% 46d | Missed |
DROP2024-12-12$44.50 RISE2025-04-16$22.99 PEAK2025-06-10$26.92 180d | -48.3% 125d | Missed | Missed | — | — | +17.1% 55d | Missed |
DROP2024-02-28$54.74 RISE2024-07-09$36.99 PEAK2024-09-19$50.09 204d | -32.4% 132d | Missed | Missed | — | — | +35.4% 72d | Missed |
DROP2023-08-08$65.00 RISE2023-10-20$44.49 PEAK2024-01-04$63.45 149d | -31.6% 73d | Missed | Missed | — | — | +42.6% 76d | Missed |
DROP2023-04-21$43.84 RISE2023-04-28$35.77 PEAK2023-07-20$63.25 90d | -18.4% 7d | Missed | Missed | — | — | +76.8% 83d | Missed |
DROP2022-04-13$42.29 RISE2022-06-13$29.79 PEAK2022-08-08$37.75 117d | -29.6% 61d | Missed | Missed | — | — | +26.7% 56d | Missed |
DROP2022-04-13$42.29 RISE2022-05-09$31.76 PEAK2022-06-07$41.41 55d | -24.9% 26d | Missed | Missed | — | — | +30.4% 29d | Missed |
DROP2021-08-03$21.49 RISE2021-10-28$18.14 PEAK2022-01-10$25.83 160d | -15.6% 86d | Missed | Missed | — | — | +42.4% 74d | Missed |
DROP2021-08-03$21.49 RISE2021-09-10$17.83 PEAK2021-11-12$21.30 101d | -17.0% 38d | Missed | Missed | — | — | +19.5% 63d | Missed |
DROP2021-01-07$20.65 RISE2021-04-12$17.11 PEAK2021-06-25$20.92 169d | -17.1% 95d | Missed | Missed | — | — | +22.3% 74d | Missed |
DROP2020-10-23$20.84 RISE2021-03-04$17.21 PEAK2021-05-14$19.97 203d | -17.4% 132d | Missed | Missed | — | — | +16.0% 71d | Missed |
1–15 / 18 1 / 2 | |||||||
Discover Xeris Biopharma (XERS) revenue growth and an inflection point driven by its expanding injectable portfolio.
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is among the best pharmaceutical stocks on this list. TheFly reported on May 13 that Wells Fargo downgraded AMPH to Equal Weight from Overweight, with the price objective reduced to $19 from $30 in a […]
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 2.8% in the morning session after Wells Fargo downgraded the company's stock to 'Equalweight' from 'Overweight' and significantly lowered its price target.
Amphastar Pharmaceuticals’ first quarter was marked by flat revenue and a significant shortfall in non-GAAP profit compared to analyst expectations, prompting a negative market reaction. Management cited continued pricing pressure, especially in its branded diabetes product BAQSIMI, and increased competition in selected product categories as key drivers behind the results. CFO William Peters acknowledged, “The pricing issue that we've been encountering appears to be potentially the increase of -
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at pharmaceuticals stocks, starting with Amphastar Pharmaceuticals (NASDAQ:AMPH).
Amphastar Pharmaceuticals, Inc.'s ( NASDAQ:AMPH ) earnings announcement last week didn't impress shareholders. However...
Analysts downgraded DOCS, MWH, WHR, AMPH, and WIX and lowered price targets. See how analysts view these stocks. Considering WHR stock? See analyst opinions.
Wells Fargo analyst Benjamin Burnett downgrades Amphastar Pharma (NASDAQ:AMPH) from Overweight to Equal-Weight and lowers the price target from $30 to $19.
Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference. Bill Peters, chief financial officer of Amphastar
Amphastar Pharmaceuticals, Inc. (AMPH) Bank of America Global Healthcare Conference 2026 May 13, 2026 6:00 PM EDTCompany ParticipantsWilliam Peters - CFO,...
Presenter SpeechUnknown Analyst My name is Jason Gerberry. I cover pharma and biotech at BofA, and I'm pleased to be introducing Amphastar Pharmaceuticals. And joining us from Amphastar. We have
Injectables Inhalation Intranasal New Molecular Peptides Proprietary 2026 Bank of America Health Care Conference May...
The analyst modeled fair value for Amphastar Pharmaceuticals was trimmed from US$28.00 to about US$26.86, pointing to a slightly lower price target being used in current research. Recent commentary links these moves to more cautious views on revenue guidance and execution, even as AMP-015 and AMP-007 win approvals and keep some analysts constructive on the stock. In the sections that follow, you will see how this evolving narrative is shaping expectations and what it may mean for your own...
Piper Sandler analyst David Amsellem reiterates Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $25 to $21.
There's been a notable change in appetite for Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) shares in the week since...
Amphastar Pharmaceuticals, Inc. reported past first-quarter 2026 results with net revenues of US$171.17 million, but net income dropped to US$6.42 million and diluted EPS fell to US$0.14 amid higher costs. Despite launching its new Ipratropium Bromide HFA inhalation product and entering a synthetic corticotropin license agreement, Amphastar’s sharply lower profitability and missed earnings expectations raised concerns about cost pressures on the business. Next, we’ll examine how this profit...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 May 07, 2026 Net revenues of $171.2 million for the three months...
Wall Street analysts changed outlook on top names. Check all changes on analyst ratings page. See what analysts think about HUBS stock.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AMPH | -13.85% | -10.28% | -29.61% | -26.68% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -16.82% | -4.57% | -26.17% | -39.37% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 1.61M | $31.49M | 0.00% | Added+4.9% | 2026-03-31 |
| DEShaw | quant | 665.5K | $13.04M | 0.01% | Added+19.5% | 2026-03-31 |
| RenTech | quant | 553.9K | $10.85M | 0.02% | Added+1.7% | 2026-03-31 |
| TwoSigma | quant | 138.1K | $2.71M | 0.00% | Added+40.0% | 2026-03-31 |
| FidelityFMR | fundamental | 1.3K | $25.35K | 0.00% | Trimmed-63.3% | 2026-03-31 |
| TRowePrice | fundamental | 44.9K | $880 | 0.00% | Added+22.0% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | 0.67 | — | — |
| 2026-05-07 | 0.71 | 0.42 | -40.46% |
| 2026-02-26 | 0.92 | 0.73 | -20.50% |
| 2025-11-06 | 0.83 | 0.93 | +12.68% |
| 2025-08-07 | 0.74 | 0.85 | +14.62% |
| 2025-05-07 | 0.69 | 0.74 | +7.61% |
| 2025-02-27 | 0.94 | 0.92 | -1.95% |
| 2024-11-06 | 0.98 | 0.96 | -2.13% |
| 2024-08-07 | 0.75 | 0.94 | +25.08% |
| 2024-05-07 | 0.79 | 1.04 | +32.23% |
| 2024-02-28 | 0.91 | 0.88 | -3.30% |
| 2023-11-08 | 0.69 | 1.15 | +66.67% |
| 2023-08-08 | 0.56 | 0.65 | +16.07% |
| 2023-05-09 | 0.50 | 0.62 | +25.25% |
| 2023-02-28 | 0.40 | 0.73 | +82.50% |
| 2022-11-07 | 0.39 | 0.38 | -3.39% |